基因组景观和主要丸淋巴瘤的独特分子亚型
Weilong Zhang1, Ping Yang1, Yaru Yang1
1Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Journal of translational medicine
|May 1, 2024
概括
初级丸淋巴瘤 (PTL) 遗传分析显示有两种亚型,C1和C2,预后不同. 瘤突变负担 (TMB) 是PTL结果和复发的关键预测因素.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 免疫学 免疫学 免疫学
背景情况:
- 初级丸淋巴瘤 (PTL) 是一种罕见的癌症,主要影响老年男性,通常呈现为扩散性大B细胞淋巴瘤 (DLBCL).
- PTL的治疗反应有限,复发率高,缺乏全面的遗传特征和分子类型研究.
- 现有的DLBCL遗传分析已经结合了有限的PTL样本,阻碍了对PTL特异性分子特征的详细理解.
研究的目的:
- 为了全面总结共同的突变特征,复制数变异 (CNVs) 和PTL的分子亚型.
- 调查遗传突变和瘤突变负担 (TMB) 在PTL的预后意义.
- 建立PTL的分子类型,以指导预后和治疗策略.
主要方法:
- 整体外组测序 (WES) 在25名PTL患者的队列中进行.
- 分析了突变频率,拷贝数变异 (CNVs) 和分子亚型.
- 瘤突变负担 (TMB) 被计算并与临床结果相关联.
主要成果:
- 在HLA,CDKN2A和MYD88基因中观察到高突变频率.
- 确定了两个核心突变特征:基因组不稳定性 (TP53,CDKN2A) 和与免疫相关的基因 (HLA,MYD88,CD79B).
- 在分子类型上,PTL患者被分为C1 (TP53突变) 和C2 (HLA突变) 亚型,尽管有TP53突变,C1的预后更好,C2的预后更差,与HLA缺失和免疫逃逸有关.
- 发现瘤突变负担 (TMB) 可以预测预后和复发率.
结论:
- 基于突变特征的PTL分子类型分为C1和C2亚型对于准确的预后至关重要.
- 具有TP53突变的C1亚型在PTL中表现出比C2亚型更好的预后.
- 瘤突变负担 (TMB) 作为一个有价值的生物标志物,用于预测PTL的预后和复发,为治疗决策提供信息.
相关概念视频
Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...


